- Home
- FT vs TIL Comparison
FT vs TIL Comparison
Compare FT & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- TIL
- Stock Information
- Founded
- FT 1988
- TIL 2018
- Country
- FT United States
- TIL United States
- Employees
- FT N/A
- TIL N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- TIL Health Care
- Exchange
- FT Nasdaq
- TIL Nasdaq
- Market Cap
- FT 192.5M
- TIL 177.1M
- IPO Year
- FT N/A
- TIL 2021
- Fundamental
- Price
- FT $7.97
- TIL $24.24
- Analyst Decision
- FT
- TIL Buy
- Analyst Count
- FT 0
- TIL 6
- Target Price
- FT N/A
- TIL $120.50
- AVG Volume (30 Days)
- FT 63.0K
- TIL 142.0K
- Earning Date
- FT 01-01-0001
- TIL 11-12-2025
- Dividend Yield
- FT 7.85%
- TIL N/A
- EPS Growth
- FT N/A
- TIL N/A
- EPS
- FT N/A
- TIL N/A
- Revenue
- FT N/A
- TIL N/A
- Revenue This Year
- FT N/A
- TIL N/A
- Revenue Next Year
- FT N/A
- TIL N/A
- P/E Ratio
- FT N/A
- TIL N/A
- Revenue Growth
- FT N/A
- TIL N/A
- 52 Week Low
- FT $5.97
- TIL $10.80
- 52 Week High
- FT $7.23
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- FT 58.26
- TIL 43.99
- Support Level
- FT $7.86
- TIL $22.67
- Resistance Level
- FT $7.99
- TIL $25.50
- Average True Range (ATR)
- FT 0.07
- TIL 2.43
- MACD
- FT -0.00
- TIL -0.52
- Stochastic Oscillator
- FT 81.81
- TIL 16.39
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.